The necessity of a robust Angelman syndrome pipeline is indispensable at the current moment because of a shortage of any approved therapy option available in the market.
The Angelman Syndrome current treatment landscape consists of symptomatic therapy options worth USD 330.2 million in 2017.
Treatment entirely focuses on the management of symptoms and supporting the health and well-being of the affected child or adult.
The management focusses on the therapies for the physical and neurological problems emphasising on the specific cognitive profiles and behavioural features of the condition.
The Angelman syndrome treatment includes Speech therap...
